| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.971 | 0.001 | 0.971 | Vasodilator, peripheral | 0.916 0.002 DBMET03506 0.821 0.004 DBMET03507 0.943 0.002 DBMET03508 0.945 0.002 DBMET03509 | ||
| 0.867 | 0.003 | 0.931 | Antithrombotic | 0.839 0.004 DBMET03506 0.611 0.015 DBMET03507 0.848 0.003 DBMET03508 0.931 0.002 DBMET03509 | DBMET03509 | |
| 0.804 | 0.004 | 0.872 | Platelet antagonist | 0.86 0.004 DBMET03506 0.746 0.005 DBMET03507 0.872 0.004 DBMET03508 0.733 0.005 DBMET03509 | DBMET03508 | |
| 0.735 | 0.011 | 0.804 | Cyclophilin D inhibitor | 0.804 0.006 DBMET03506 0.688 0.015 DBMET03507 0.759 0.009 DBMET03508 0.786 0.007 DBMET03509 | DBMET03506 | |
| 0.657 | 0.005 | 0.657 | Hypolipemic | 0.467 0.015 DBMET03506 0.462 0.016 DBMET03507 0.531 0.01 DBMET03508 0.601 0.006 DBMET03509 | ||
| 0.655 | 0.012 | 0.723 | Cholesterol antagonist | 0.576 0.022 DBMET03506 0.368 0.058 DBMET03507 0.582 0.021 DBMET03508 0.723 0.006 DBMET03509 | DBMET03509 | |
| 0.637 | 0.001 | 0.637 | Prostaglandin agonist | 0.48 0.001 DBMET03506 0.293 0.002 DBMET03507 0.56 0.001 DBMET03508 0.392 0.002 DBMET03509 | ||
| 0.59 | 0.005 | 0.683 | Platelet aggregation inhibitor | 0.683 0.005 DBMET03506 0.524 0.008 DBMET03507 0.624 0.005 DBMET03508 0.36 0.024 DBMET03509 | DBMET03506 | |
| 0.58 | 0.007 | 0.594 | Vasodilator | 0.552 0.008 DBMET03506 0.5 0.012 DBMET03507 0.552 0.008 DBMET03508 0.594 0.006 DBMET03509 | DBMET03509 | |
| 0.506 | 0.001 | 0.506 | Prostaglandin E2 agonist | 0.373 0.002 DBMET03506 0.08 0.004 DBMET03507 0.408 0.001 DBMET03508 0.195 0.003 DBMET03509 | ||
| 0.509 | 0.026 | 0.509 | 5 Hydroxytryptamine release stimulant | 0.171 0.151 DBMET03506 0.427 0.04 DBMET03509 | ||
| 0.482 | 0.001 | 0.482 | Prostacyclin agonist | 0.473 0.001 DBMET03506 0.334 0.001 DBMET03507 0.447 0.001 DBMET03508 0.305 0.002 DBMET03509 | ||
| 0.497 | 0.023 | 0.497 | Spasmolytic | 0.465 0.028 DBMET03506 0.401 0.04 DBMET03507 0.397 0.041 DBMET03508 0.49 0.024 DBMET03509 | ||
| 0.449 | 0.001 | 0.449 | Prostaglandin EP2 agonist | 0.248 0.001 DBMET03506 0.073 0.004 DBMET03507 0.278 0.001 DBMET03508 0.21 0.002 DBMET03509 | ||
| 0.481 | 0.038 | 0.555 | Immunosuppressant | 0.44 0.05 DBMET03506 0.398 0.064 DBMET03507 0.445 0.048 DBMET03508 0.555 0.02 DBMET03509 | DBMET03509 | |
| 0.481 | 0.042 | 0.651 | Antiobesity | 0.651 0.015 DBMET03506 0.336 0.094 DBMET03507 0.591 0.022 DBMET03508 0.389 0.07 DBMET03509 | DBMET03506 | |
| 0.443 | 0.003 | 0.538 | Gastric antisecretory | 0.395 0.004 DBMET03506 0.2 0.012 DBMET03507 0.538 0.003 DBMET03508 0.19 0.014 DBMET03509 | DBMET03508 | |
| 0.431 | 0.004 | 0.431 | Prostaglandin EP2 antagonist | 0.261 0.005 DBMET03506 0.135 0.012 DBMET03507 0.257 0.005 DBMET03508 0.246 0.005 DBMET03509 | ||
| 0.419 | 0.004 | 0.419 | Phospholipase A2 inhibitor | 0.355 0.007 DBMET03506 0.192 0.047 DBMET03507 0.353 0.008 DBMET03508 0.395 0.005 DBMET03509 | ||
| 0.435 | 0.026 | 0.653 | Vasodilator, coronary | 0.423 0.029 DBMET03506 0.453 0.023 DBMET03507 0.347 0.057 DBMET03508 0.653 0.005 DBMET03509 | DBMET03509 | |
| 0.431 | 0.041 | 0.614 | Immunostimulant | 0.314 0.075 DBMET03506 0.222 0.108 DBMET03507 0.256 0.094 DBMET03508 0.614 0.015 DBMET03509 | DBMET03509 | |
| 0.413 | 0.025 | 0.536 | Hypoglycemic | 0.453 0.02 DBMET03506 0.358 0.036 DBMET03507 0.395 0.028 DBMET03508 0.536 0.012 DBMET03509 | DBMET03509 | |
| 0.386 | 0.019 | 0.435 | Cyclic AMP phosphodiesterase inhibitor | 0.303 0.041 DBMET03506 0.227 0.076 DBMET03507 0.166 0.127 DBMET03508 0.435 0.012 DBMET03509 | DBMET03509 | |
| 0.405 | 0.037 | 0.512 | Apoptosis antagonist | 0.41 0.035 DBMET03506 0.343 0.059 DBMET03507 0.382 0.044 DBMET03508 0.512 0.019 DBMET03509 | DBMET03509 | |
| 0.385 | 0.022 | 0.416 | Sodium/bile acid cotransporter inhibitor | 0.416 0.013 DBMET03506 0.391 0.019 DBMET03507 0.401 0.017 DBMET03508 0.312 0.069 DBMET03509 | DBMET03506 | |
| 0.369 | 0.015 | 0.444 | Platelet adhesion inhibitor | 0.439 0.008 DBMET03506 0.369 0.015 DBMET03507 0.403 0.011 DBMET03508 0.444 0.008 DBMET03509 | DBMET03509 | |
| 0.407 | 0.062 | 0.72 | Transcription factor NF kappa B inhibitor | 0.326 0.084 DBMET03506 0.222 0.149 DBMET03507 0.38 0.068 DBMET03508 0.72 0.018 DBMET03509 | DBMET03509 | |
| 0.33 | 0.009 | 0.33 | Cholesterol synthesis inhibitor | 0.286 0.013 DBMET03506 0.157 0.041 DBMET03507 0.26 0.016 DBMET03508 0.191 0.029 DBMET03509 | ||
| 0.327 | 0.023 | 0.458 | Hepatoprotectant | 0.341 0.02 DBMET03506 0.271 0.038 DBMET03507 0.338 0.021 DBMET03508 0.458 0.009 DBMET03509 | DBMET03509 | |
| 0.349 | 0.046 | 0.454 | Interleukin 2 agonist | 0.312 0.066 DBMET03506 0.264 0.104 DBMET03507 0.34 0.05 DBMET03508 0.454 0.015 DBMET03509 | DBMET03509 | |
| 0.373 | 0.089 | 0.651 | Antibacterial | 0.301 0.135 DBMET03506 0.313 0.126 DBMET03507 0.381 0.085 DBMET03508 0.651 0.013 DBMET03509 | DBMET03509 | |
| 0.284 | 0.003 | 0.284 | Prostaglandin F2 alpha antagonist | 0.147 0.005 DBMET03506 0.096 0.013 DBMET03507 0.159 0.004 DBMET03508 0.164 0.004 DBMET03509 | ||
| 0.28 | 0.002 | 0.294 | Prostaglandin D2 agonist | 0.257 0.002 DBMET03506 0.119 0.002 DBMET03507 0.294 0.002 DBMET03508 0.089 0.003 DBMET03509 | DBMET03508 | |
| 0.388 | 0.119 | 0.614 | Apoptosis agonist | 0.354 0.136 DBMET03506 0.243 0.222 DBMET03507 0.501 0.074 DBMET03508 0.614 0.046 DBMET03509 | DBMET03509 | |
| 0.307 | 0.045 | 0.399 | Interleukin agonist | 0.222 0.101 DBMET03506 0.214 0.108 DBMET03508 0.399 0.019 DBMET03509 | DBMET03509 | |
| 0.281 | 0.021 | 0.281 | Insulin sensitizer | 0.232 0.046 DBMET03506 0.196 0.077 DBMET03507 0.209 0.064 DBMET03508 0.168 0.11 DBMET03509 | ||
| 0.305 | 0.051 | 0.415 | Tumour necrosis factor alpha release inhibitor | 0.184 0.123 DBMET03506 0.209 0.101 DBMET03508 0.415 0.024 DBMET03509 | DBMET03509 | |
| 0.375 | 0.127 | 0.471 | Caspase 9 stimulant | 0.389 0.117 DBMET03506 0.352 0.144 DBMET03507 0.41 0.105 DBMET03508 0.471 0.072 DBMET03509 | DBMET03509 | |
| 0.246 | 0.003 | 0.317 | Thromboxane antagonist | 0.207 0.004 DBMET03506 0.11 0.008 DBMET03507 0.317 0.003 DBMET03508 0.074 0.024 DBMET03509 | DBMET03508 | |
| 0.297 | 0.058 | 0.297 | Cardiotonic | 0.285 0.063 DBMET03506 0.189 0.13 DBMET03507 0.193 0.125 DBMET03508 0.213 0.107 DBMET03509 | ||
| 0.234 | 0.01 | 0.251 | Arachidonic acid antagonist | 0.251 0.005 DBMET03506 0.244 0.007 DBMET03507 0.243 0.007 DBMET03508 | DBMET03506 | |
| 0.328 | 0.11 | 0.418 | Histamine release inhibitor | 0.328 0.11 DBMET03506 0.418 0.066 DBMET03509 | DBMET03509 | |
| 0.222 | 0.003 | 0.296 | Thromboxane A2 antagonist | 0.188 0.003 DBMET03506 0.1 0.007 DBMET03507 0.296 0.003 DBMET03508 0.069 0.022 DBMET03509 | DBMET03508 | |
| 0.277 | 0.058 | 0.54 | Angiogenesis stimulant | 0.249 0.07 DBMET03506 0.19 0.1 DBMET03507 0.28 0.057 DBMET03508 0.54 0.01 DBMET03509 | DBMET03509 | |
| 0.219 | 0.001 | 0.219 | Prostaglandin EP4 agonist | 0.147 0.002 DBMET03506 0.033 0.007 DBMET03507 0.146 0.002 DBMET03508 0.137 0.003 DBMET03509 | ||
| 0.25 | 0.033 | 0.283 | Lipocortins synthesis antagonist | 0.283 0.024 DBMET03506 0.269 0.028 DBMET03507 0.257 0.031 DBMET03508 0.179 0.072 DBMET03509 | DBMET03506 | |
| 0.263 | 0.048 | 0.412 | Nitric oxide antagonist | 0.248 0.052 DBMET03506 0.214 0.063 DBMET03507 0.282 0.044 DBMET03508 0.412 0.024 DBMET03509 | DBMET03509 | |
| 0.37 | 0.158 | 0.688 | Antiinflammatory | 0.318 0.198 DBMET03506 0.438 0.116 DBMET03508 0.688 0.033 DBMET03509 | DBMET03509 | |
| 0.226 | 0.018 | 0.244 | Neurotrophic factor | 0.192 0.031 DBMET03506 0.163 0.049 DBMET03507 0.244 0.013 DBMET03508 0.194 0.03 DBMET03509 | DBMET03508 | |
| 0.244 | 0.043 | 0.244 | P-glycoprotein inhibitor | 0.18 0.079 DBMET03506 0.171 0.088 DBMET03507 0.226 0.05 DBMET03508 0.24 0.045 DBMET03509 | ||
| 0.229 | 0.03 | 0.229 | Phospholipase C inhibitor | 0.191 0.05 DBMET03506 0.173 0.069 DBMET03507 0.192 0.049 DBMET03508 0.138 0.132 DBMET03509 | ||
| 0.22 | 0.023 | 0.25 | DNA polymerase I inhibitor | 0.25 0.017 DBMET03506 0.185 0.033 DBMET03507 0.219 0.023 DBMET03508 0.203 0.027 DBMET03509 | DBMET03506 | |
| 0.202 | 0.018 | 0.248 | Bronchodilator | 0.248 0.013 DBMET03506 0.106 0.057 DBMET03507 0.21 0.017 DBMET03508 0.083 0.082 DBMET03509 | DBMET03506 | |
| 0.189 | 0.006 | 0.189 | Leukotriene antagonist | 0.119 0.015 DBMET03506 0.075 0.036 DBMET03507 0.149 0.01 DBMET03508 0.106 0.019 DBMET03509 | ||
| 0.218 | 0.035 | 0.306 | Interferon gamma antagonist | 0.194 0.043 DBMET03506 0.16 0.066 DBMET03507 0.187 0.046 DBMET03508 0.306 0.019 DBMET03509 | DBMET03509 | |
| 0.201 | 0.02 | 0.296 | Expectorant | 0.161 0.031 DBMET03506 0.129 0.045 DBMET03507 0.141 0.039 DBMET03508 0.296 0.009 DBMET03509 | DBMET03509 | |
| 0.181 | 0.001 | 0.181 | Thromboxane agonist | 0.125 0.001 DBMET03506 0.061 0.002 DBMET03507 0.134 0.001 DBMET03508 0.03 0.003 DBMET03509 | ||
| 0.185 | 0.008 | 0.23 | Prostaglandin antagonist | 0.217 0.006 DBMET03506 0.079 0.023 DBMET03507 0.23 0.005 DBMET03508 | DBMET03508 | |
| 0.21 | 0.042 | 0.21 | Antipruritic | 0.178 0.066 DBMET03506 | ||
| 0.205 | 0.039 | 0.22 | Melanin inhibitor | 0.158 0.071 DBMET03506 0.134 0.107 DBMET03507 0.145 0.089 DBMET03508 0.22 0.034 DBMET03509 | DBMET03509 | |
| 0.187 | 0.023 | 0.242 | Microtubule formation inhibitor | 0.153 0.036 DBMET03506 0.123 0.058 DBMET03507 0.174 0.027 DBMET03508 0.242 0.011 DBMET03509 | DBMET03509 | |
| 0.199 | 0.038 | 0.2 | ATPase inhibitor | 0.183 0.054 DBMET03506 0.188 0.049 DBMET03508 0.2 0.037 DBMET03509 | DBMET03509 | |
| 0.312 | 0.152 | 0.312 | 5 Hydroxytryptamine release inhibitor | 0.283 0.185 DBMET03506 0.242 0.239 DBMET03507 0.295 0.17 DBMET03509 | ||
| 0.17 | 0.01 | 0.175 | Anabolic | 0.175 0.008 DBMET03506 0.163 0.012 DBMET03507 0.163 0.012 DBMET03508 0.096 0.068 DBMET03509 | DBMET03506 | |
| 0.245 | 0.086 | 0.503 | Antioxidant | 0.253 0.082 DBMET03506 0.196 0.116 DBMET03507 0.272 0.073 DBMET03508 0.503 0.02 DBMET03509 | DBMET03509 | |
| 0.2 | 0.042 | 0.244 | Protein kinase stimulant | 0.187 0.047 DBMET03506 0.201 0.041 DBMET03508 0.244 0.028 DBMET03509 | DBMET03509 | |
| 0.168 | 0.015 | 0.177 | Ca2+-transporting ATPase inhibitor | 0.169 0.014 DBMET03506 0.177 0.009 DBMET03507 0.163 0.019 DBMET03508 0.166 0.016 DBMET03509 | DBMET03507 | |
| 0.185 | 0.04 | 0.196 | Bone formation stimulant | 0.131 0.076 DBMET03506 0.12 0.085 DBMET03507 0.196 0.037 DBMET03508 0.159 0.052 DBMET03509 | DBMET03508 | |
| 0.174 | 0.031 | 0.178 | Adenylate cyclase stimulant | 0.178 0.027 DBMET03506 0.155 0.054 DBMET03507 0.177 0.028 DBMET03508 | DBMET03506 | |
| 0.146 | 0.005 | 0.146 | Leukotriene B4 antagonist | 0.085 0.014 DBMET03506 0.057 0.032 DBMET03507 0.067 0.021 DBMET03508 0.091 0.012 DBMET03509 | ||
| 0.143 | 0.004 | 0.242 | Prostacyclin antagonist | 0.219 0.004 DBMET03506 0.154 0.004 DBMET03507 0.242 0.003 DBMET03508 0.038 0.019 DBMET03509 | DBMET03508 | |
| 0.154 | 0.019 | 0.181 | Toll-Like receptor 4 antagonist | 0.114 0.05 DBMET03506 0.109 0.056 DBMET03507 0.12 0.043 DBMET03508 0.181 0.009 DBMET03509 | DBMET03509 | |
| 0.153 | 0.019 | 0.153 | Electron transport complex I inhibitor | 0.112 0.058 DBMET03509 | ||
| 0.201 | 0.074 | 0.285 | Anesthetic general | 0.285 0.037 DBMET03506 0.189 0.081 DBMET03507 0.157 0.107 DBMET03508 0.16 0.103 DBMET03509 | DBMET03506 | |
| 0.263 | 0.137 | 0.282 | Toll-Like receptor agonist | 0.282 0.122 DBMET03506 0.225 0.173 DBMET03508 | DBMET03506 | |
| 0.165 | 0.04 | 0.203 | Protein-tyrosine phosphatase 1B inhibitor | 0.193 0.031 DBMET03506 0.196 0.03 DBMET03507 0.203 0.028 DBMET03508 0.131 0.055 DBMET03509 | DBMET03508 | |
| 0.18 | 0.056 | 0.217 | Protein-tyrosine phosphatase inhibitor | 0.213 0.042 DBMET03506 0.205 0.045 DBMET03507 0.217 0.041 DBMET03508 0.14 0.09 DBMET03509 | DBMET03508 | |
| 0.131 | 0.008 | 0.131 | Peroxisome proliferator-activated receptor alpha agonist | 0.108 0.01 DBMET03506 0.046 0.035 DBMET03507 0.104 0.011 DBMET03508 | ||
| 0.184 | 0.063 | 0.184 | Succinate dehydrogenase inhibitor | 0.178 0.07 DBMET03506 0.172 0.078 DBMET03507 0.16 0.095 DBMET03508 | ||
| 0.129 | 0.018 | 0.138 | Peroxisome proliferator-activated receptor gamma agonist | 0.138 0.016 DBMET03506 0.101 0.027 DBMET03507 0.12 0.02 DBMET03508 0.064 0.054 DBMET03509 | DBMET03506 | |
| 0.11 | 0.001 | 0.11 | Prostaglandin F2 alpha agonist | 0.08 0.002 DBMET03506 0.032 0.008 DBMET03507 0.087 0.002 DBMET03508 0.048 0.004 DBMET03509 | ||
| 0.122 | 0.016 | 0.128 | Leukotriene synthesis inhibitor | 0.099 0.027 DBMET03506 0.128 0.014 DBMET03507 0.102 0.025 DBMET03508 0.06 0.055 DBMET03509 | DBMET03507 | |
| 0.128 | 0.022 | 0.128 | Adrenaline agonist | 0.121 0.025 DBMET03506 0.079 0.059 DBMET03507 | ||
| 0.165 | 0.06 | 0.233 | Insulin secretagoues | 0.219 0.028 DBMET03506 0.219 0.027 DBMET03507 0.164 0.06 DBMET03508 0.233 0.023 DBMET03509 | DBMET03509 | |
| 0.11 | 0.004 | 0.11 | Prostaglandin EP4 antagonist | 0.041 0.011 DBMET03506 0.039 0.011 DBMET03508 | ||
| 0.109 | 0.005 | 0.109 | Prostaglandin EP3 antagonist | 0.093 0.006 DBMET03506 0.053 0.009 DBMET03508 0.028 0.023 DBMET03509 | ||
| 0.146 | 0.042 | 0.146 | Vanilloid 1 agonist | 0.113 0.107 DBMET03506 0.113 0.106 DBMET03507 0.134 0.06 DBMET03508 0.136 0.056 DBMET03509 | ||
| 0.121 | 0.019 | 0.121 | ATPase (Vacuolar H+) inhibitor | 0.114 0.024 DBMET03506 0.11 0.028 DBMET03507 0.121 0.019 DBMET03508 0.116 0.023 DBMET03509 | ||
| 0.167 | 0.07 | 0.232 | Thrombolytic | 0.195 0.054 DBMET03506 0.133 0.096 DBMET03507 0.215 0.045 DBMET03508 0.232 0.039 DBMET03509 | DBMET03509 | |
| 0.197 | 0.103 | 0.309 | Peptidyltransferase inhibitor | 0.211 0.085 DBMET03506 0.174 0.139 DBMET03507 0.199 0.1 DBMET03508 0.309 0.022 DBMET03509 | DBMET03509 | |
| 0.142 | 0.053 | 0.142 | Anesthetic local | |||
| 0.139 | 0.051 | 0.387 | Monophenol monooxygenase inhibitor | 0.131 0.055 DBMET03506 0.132 0.055 DBMET03508 0.387 0.012 DBMET03509 | DBMET03509 | |
| 0.214 | 0.128 | 0.285 | Gastrin inhibitor | 0.266 0.061 DBMET03506 0.285 0.045 DBMET03508 | DBMET03508 | |
| 0.085 | 0.003 | 0.085 | HMG CoA reductase inhibitor | 0.043 0.012 DBMET03506 0.055 0.005 DBMET03507 0.048 0.008 DBMET03508 0.072 0.004 DBMET03509 | ||
| 0.088 | 0.007 | 0.099 | Peroxisome proliferator-activated receptor delta agonist | 0.099 0.005 DBMET03506 0.035 0.021 DBMET03507 0.053 0.012 DBMET03508 | DBMET03506 | |
| 0.142 | 0.062 | 0.227 | Farnesoid X receptor antagonist | 0.178 0.03 DBMET03506 0.146 0.057 DBMET03507 0.227 0.015 DBMET03508 | DBMET03508 | |
| 0.118 | 0.039 | 0.216 | Antineoplastic antibiotic | 0.107 0.043 DBMET03506 0.097 0.047 DBMET03507 0.135 0.035 DBMET03508 0.216 0.018 DBMET03509 | DBMET03509 | |
| 0.091 | 0.017 | 0.091 | Prostaglandin E2 antagonist | 0.057 0.03 DBMET03506 | ||
| 0.102 | 0.03 | 0.113 | Na+ K+ transporting ATPase inhibitor | 0.108 0.024 DBMET03506 0.086 0.045 DBMET03507 0.109 0.024 DBMET03508 0.113 0.021 DBMET03509 | DBMET03509 | |
| 0.087 | 0.016 | 0.102 | Nitric oxide donor | 0.063 0.044 DBMET03506 0.058 0.053 DBMET03508 0.102 0.008 DBMET03509 | DBMET03509 | |
| 0.135 | 0.064 | 0.135 | Toll-Like receptor 2 antagonist | |||
| 0.071 | 0.001 | 0.072 | Thromboxane A2 agonist | 0.07 0.001 DBMET03506 0.038 0.003 DBMET03507 0.072 0.001 DBMET03508 | DBMET03508 | |
| 0.081 | 0.015 | 0.081 | Sphingosine kinase inhibitor | |||
| 0.231 | 0.166 | 0.278 | Toll-Like receptor 7 agonist | 0.278 0.125 DBMET03506 0.222 0.176 DBMET03508 | DBMET03506 | |
| 0.118 | 0.058 | 0.135 | Estrogen antagonist | 0.135 0.032 DBMET03506 0.114 0.066 DBMET03507 0.128 0.041 DBMET03508 | DBMET03506 | |
| 0.092 | 0.033 | 0.146 | Estrogen receptor alpha antagonist | 0.146 0.012 DBMET03506 0.084 0.043 DBMET03507 0.124 0.017 DBMET03508 | DBMET03506 | |
| 0.116 | 0.059 | 0.127 | Mucolytic | 0.127 0.048 DBMET03506 0.108 0.067 DBMET03507 0.113 0.061 DBMET03508 | DBMET03506 | |
| 0.129 | 0.073 | 0.138 | Interleukin 4 antagonist | 0.109 0.102 DBMET03506 0.138 0.062 DBMET03509 | DBMET03509 | |
| 0.141 | 0.085 | 0.303 | Diuretic | 0.303 0.022 DBMET03506 0.17 0.061 DBMET03507 0.163 0.066 DBMET03508 | DBMET03506 | |
| 0.098 | 0.048 | 0.132 | Androgen antagonist | 0.132 0.028 DBMET03506 0.084 0.06 DBMET03507 0.074 0.073 DBMET03508 | DBMET03506 | |
| 0.077 | 0.028 | 0.109 | Glutamate (mGluR6) antagonist | 0.109 0.008 DBMET03506 0.092 0.014 DBMET03507 0.087 0.018 DBMET03508 | DBMET03506 | |
| 0.123 | 0.074 | 0.169 | Cyclooxygenase 3 inhibitor | 0.158 0.042 DBMET03506 0.106 0.095 DBMET03507 0.102 0.1 DBMET03508 0.169 0.034 DBMET03509 | DBMET03509 | |
| 0.156 | 0.111 | 0.234 | Psychostimulant | 0.234 0.065 DBMET03506 0.15 0.116 DBMET03507 | DBMET03506 | |
| 0.099 | 0.056 | 0.115 | Prolactin inhibitor | 0.112 0.044 DBMET03506 0.115 0.042 DBMET03508 | DBMET03508 | |
| 0.097 | 0.054 | 0.097 | ABCA1 expression enhancer | 0.093 0.06 DBMET03506 | ||
| 0.081 | 0.041 | 0.11 | Phosphofructokinase-1 inhibitor | 0.11 0.028 DBMET03506 0.078 0.042 DBMET03507 0.085 0.039 DBMET03508 0.074 0.045 DBMET03509 | DBMET03506 | |
| 0.204 | 0.164 | 0.278 | Caspase 3 stimulant | 0.204 0.163 DBMET03506 0.278 0.091 DBMET03508 0.249 0.113 DBMET03509 | DBMET03508 | |
| 0.063 | 0.023 | 0.063 | Leukotriene C antagonist | 0.062 0.025 DBMET03506 0.057 0.036 DBMET03508 | ||
| 0.11 | 0.071 | 0.185 | Photosensitizer | 0.185 0.016 DBMET03506 0.101 0.087 DBMET03507 0.119 0.059 DBMET03508 0.115 0.063 DBMET03509 | DBMET03506 | |
| 0.065 | 0.027 | 0.071 | Lipocortins synthesis agonist | 0.069 0.023 DBMET03506 0.071 0.02 DBMET03507 0.067 0.024 DBMET03508 0.067 0.024 DBMET03509 | DBMET03507 | |
| 0.165 | 0.128 | 0.402 | Free radical scavenger | 0.178 0.116 DBMET03506 0.194 0.103 DBMET03508 0.402 0.028 DBMET03509 | DBMET03509 | |
| 0.05 | 0.014 | 0.067 | Nicotinic acid receptor 2 agonist | 0.067 0.01 DBMET03506 0.041 0.019 DBMET03507 0.049 0.014 DBMET03508 0.036 0.025 DBMET03509 | DBMET03506 | |
| 0.124 | 0.09 | 0.23 | Lipid peroxidase inhibitor | 0.23 0.031 DBMET03509 | DBMET03509 | |
| 0.13 | 0.096 | 0.259 | Hemostatic | 0.172 0.047 DBMET03506 0.128 0.099 DBMET03508 0.259 0.021 DBMET03509 | DBMET03509 | |
| 0.08 | 0.049 | 0.101 | Keratolytic | 0.101 0.03 DBMET03506 0.083 0.045 DBMET03507 0.101 0.03 DBMET03508 | DBMET03508 | |
| 0.048 | 0.016 | 0.062 | Arginase inhibitor | 0.061 0.01 DBMET03506 0.033 0.028 DBMET03507 0.044 0.019 DBMET03508 0.062 0.01 DBMET03509 | DBMET03509 | |
| 0.037 | 0.006 | 0.037 | Leukotriene B4 receptor 2 antagonist | 0.034 0.007 DBMET03506 0.024 0.013 DBMET03508 0.026 0.011 DBMET03509 | ||
| 0.086 | 0.055 | 0.104 | Vanilloid agonist | 0.091 0.046 DBMET03508 0.104 0.029 DBMET03509 | DBMET03509 | |
| 0.032 | 0.003 | 0.032 | Vitamin D receptor agonist | 0.017 0.01 DBMET03506 0.016 0.013 DBMET03507 0.018 0.009 DBMET03508 0.023 0.005 DBMET03509 | ||
| 0.04 | 0.012 | 0.04 | Leukotriene B4 receptor 1 antagonist | 0.039 0.012 DBMET03506 0.024 0.023 DBMET03509 | ||
| 0.036 | 0.009 | 0.036 | Prostaglandin EP1 antagonist | |||
| 0.109 | 0.084 | 0.109 | Aldehyde dehydrogenase inhibitor | |||
| 0.092 | 0.068 | 0.125 | Bile acid receptor antagonist | 0.125 0.016 DBMET03506 0.114 0.026 DBMET03508 | DBMET03506 | |
| 0.039 | 0.015 | 0.102 | Peroxisome proliferator-activated receptor delta antagonist | 0.102 0.005 DBMET03506 0.037 0.017 DBMET03507 0.041 0.014 DBMET03508 | DBMET03506 | |
| 0.067 | 0.043 | 0.068 | Beta adrenoreceptor antagonist | 0.068 0.041 DBMET03506 | DBMET03506 | |
| 0.063 | 0.041 | 0.064 | Prolactin release inhibitor | 0.064 0.036 DBMET03506 0.064 0.036 DBMET03507 0.061 0.047 DBMET03508 | DBMET03507 | |
| 0.037 | 0.015 | 0.037 | Calcium-independent phospholipase A2 inhibitor | |||
| 0.031 | 0.01 | 0.04 | Toll-Like receptor 4 agonist | 0.04 0.005 DBMET03509 | DBMET03509 | |
| 0.05 | 0.03 | 0.057 | Glucose-6-phosphate isomerase inhibitor | 0.057 0.021 DBMET03506 0.05 0.03 DBMET03507 0.051 0.028 DBMET03508 0.048 0.033 DBMET03509 | DBMET03506 | |
| 0.053 | 0.034 | 0.053 | Vanilloid 2 antagonist | |||
| 0.035 | 0.017 | 0.035 | ATP citrate lysase inhibitor | |||
| 0.03 | 0.012 | 0.03 | Hedgehog signaling activator | |||
| 0.084 | 0.067 | 0.095 | Antiadrenergic | 0.095 0.059 DBMET03506 | DBMET03506 | |
| 0.04 | 0.024 | 0.04 | Leukotriene C4 antagonist | 0.04 0.023 DBMET03506 0.037 0.034 DBMET03508 | ||
| 0.071 | 0.055 | 0.076 | CDC25A inhibitor | 0.076 0.048 DBMET03506 0.067 0.061 DBMET03508 | DBMET03506 | |
| 0.054 | 0.038 | 0.054 | Acyl-CoA dehydrogenase inhibitor | |||
| 0.151 | 0.136 | 0.167 | Neurotrophic factor enhancer | 0.16 0.123 DBMET03506 0.167 0.115 DBMET03507 0.162 0.121 DBMET03508 | DBMET03507 | |
| 0.063 | 0.049 | 0.063 | Beta 3 adrenoreceptor antagonist | |||
| 0.092 | 0.079 | 0.111 | Estrogen receptor beta antagonist | 0.111 0.044 DBMET03506 0.09 0.083 DBMET03507 0.101 0.063 DBMET03508 | DBMET03506 | |
| 0.022 | 0.009 | 0.126 | Free fatty acid receptor 1 agonist | 0.126 0.004 DBMET03506 0.036 0.005 DBMET03507 0.042 0.005 DBMET03508 | DBMET03506 | |
| 0.053 | 0.04 | 0.104 | Thromboxane synthase inhibitor | 0.078 0.013 DBMET03506 0.104 0.006 DBMET03508 | DBMET03508 | |
| 0.052 | 0.04 | 0.08 | Sphingosine 1-phosphate receptor 5 agonist | 0.08 0.013 DBMET03506 0.056 0.033 DBMET03508 | DBMET03506 | |
| 0.048 | 0.037 | 0.062 | Estrogen agonist | 0.062 0.029 DBMET03506 0.042 0.041 DBMET03507 0.052 0.034 DBMET03508 0.047 0.037 DBMET03509 | DBMET03506 | |
| 0.023 | 0.012 | 0.024 | Vitamin D receptor antagonist | 0.023 0.014 DBMET03506 0.022 0.015 DBMET03508 0.024 0.012 DBMET03509 | DBMET03509 | |
| 0.079 | 0.069 | 0.089 | Adrenaline antagonist | 0.089 0.061 DBMET03506 | DBMET03506 | |
| 0.068 | 0.058 | 0.074 | Peroxisome proliferator-activated receptor gamma antagonist | 0.074 0.044 DBMET03506 | DBMET03506 | |
| 0.036 | 0.026 | 0.066 | Glutamate (mGluR3) antagonist | 0.066 0.007 DBMET03506 0.039 0.023 DBMET03507 0.04 0.021 DBMET03508 | DBMET03506 | |
| 0.024 | 0.015 | 0.063 | Prostaglandin D2 antagonist | 0.061 0.005 DBMET03506 0.024 0.015 DBMET03507 0.063 0.005 DBMET03508 | DBMET03508 | |
| 0.04 | 0.032 | 0.047 | Sphingosine 1-phosphate receptor 1 agonist | 0.047 0.023 DBMET03506 | DBMET03506 | |
| 0.049 | 0.041 | 0.077 | Aconitate hydratase inhibitor | 0.077 0.015 DBMET03506 0.062 0.024 DBMET03507 0.066 0.021 DBMET03508 | DBMET03506 | |
| 0.041 | 0.035 | 0.055 | Sphingosine 1-phosphate receptor agonist | 0.055 0.02 DBMET03506 | DBMET03506 | |
| 0.048 | 0.042 | 0.093 | Protein 50S ribosomal subunit inhibitor | 0.049 0.041 DBMET03506 0.049 0.041 DBMET03508 0.093 0.015 DBMET03509 | DBMET03509 | |
| 0.08 | 0.074 | 0.08 | Interleukin 5 antagonist | |||
| 0.044 | 0.039 | 0.044 | Cholesterol esterase inhibitor | |||
| 0.042 | 0.037 | 0.058 | Mannosidase inhibitor | 0.058 0.018 DBMET03509 | DBMET03509 | |
| 0.022 | 0.018 | 0.022 | Isoleucine-tRNA ligase inhibitor | 0.022 0.018 DBMET03506 | ||
| 0.097 | 0.094 | 0.097 | TRPA1 agonist | |||
| 0.028 | 0.025 | 0.039 | Squalene synthetase inhibitor | 0.036 0.02 DBMET03508 0.039 0.018 DBMET03509 | DBMET03509 | |
| 0.049 | 0.047 | 0.049 | Beta 1 adrenoreceptor antagonist | 0.049 0.048 DBMET03506 | ||
| 0.038 | 0.036 | 0.038 | Sphingosine kinase 1 inhibitor | |||
| 0.045 | 0.044 | 0.047 | Beta 2 adrenoreceptor antagonist | 0.047 0.041 DBMET03506 | DBMET03506 | |
| 0.041 | 0.04 | 0.054 | Microtubule stabilization | 0.042 0.039 DBMET03508 0.054 0.022 DBMET03509 | DBMET03509 | |
| 0.07 | 0.071 | 0.078 | Interferon agonist | 0.078 0.055 DBMET03509 | DBMET03509 | |
| 0.014 | 0.016 | 0.023 | Thyroid hormone alpha agonist | 0.023 0.005 DBMET03506 0.017 0.011 DBMET03507 0.017 0.011 DBMET03508 | DBMET03506 | |
| 0.1 | 0.102 | 0.125 | Alpha-N-acetylglucosaminidase inhibitor | 0.125 0.072 DBMET03506 0.125 0.072 DBMET03507 | DBMET03507 | |
| 0.02 | 0.023 | 0.043 | Protein 30S ribosomal subunit inhibitor | 0.022 0.019 DBMET03506 0.043 0.009 DBMET03509 | DBMET03509 | |
| 0.119 | 0.123 | 0.136 | Growth hormone agonist | 0.136 0.1 DBMET03506 | DBMET03506 | |
| 0.117 | 0.122 | 0.198 | NOS3 expression enhancer | 0.138 0.086 DBMET03506 0.161 0.062 DBMET03507 0.15 0.072 DBMET03508 0.198 0.042 DBMET03509 | DBMET03509 | |
| 0.083 | 0.089 | 0.099 | Electrolyte absorption antagonist | 0.099 0.06 DBMET03506 | DBMET03506 | |
| 0.013 | 0.018 | 0.017 | Ileal bile acid transport inhibitor | 0.017 0.012 DBMET03506 | DBMET03506 | |
| 0.019 | 0.025 | 0.023 | Dopamine D1 agonist | 0.023 0.015 DBMET03506 0.022 0.018 DBMET03507 0.023 0.016 DBMET03509 | DBMET03509 | |
| 0.012 | 0.018 | 0.021 | G-protein-coupled receptor 120 agonist | 0.021 0.008 DBMET03506 | DBMET03506 | |
| 0.032 | 0.038 | 0.037 | Glutamate (mGluR8) antagonist | 0.037 0.023 DBMET03506 0.033 0.032 DBMET03508 | DBMET03506 | |
| 0.071 | 0.078 | 0.086 | Ornithine decarboxylase inhibitor | 0.085 0.061 DBMET03506 0.086 0.06 DBMET03508 | DBMET03508 | |
| 0.012 | 0.019 | 0.024 | Thyroid hormone alpha antagonist | 0.024 0.006 DBMET03506 | DBMET03506 | |
| 0.112 | 0.12 | 0.133 | Acetylcholine M1 receptor antagonist | 0.133 0.092 DBMET03506 | DBMET03506 | |
| 0.087 | 0.095 | 0.091 | Adenylate kinase inhibitor | 0.09 0.086 DBMET03506 0.091 0.084 DBMET03508 | DBMET03508 | |
| 0.024 | 0.035 | 0.027 | 1,3-Beta-glucan synthase inhibitor | 0.027 0.024 DBMET03509 | DBMET03509 | |
| 0.133 | 0.144 | 0.191 | Non-steroidal antiinflammatory agent | 0.191 0.079 DBMET03509 | DBMET03509 | |
| 0.037 | 0.049 | 0.091 | Glutamate (mGluR group III) antagonist | 0.091 0.006 DBMET03506 0.063 0.011 DBMET03507 0.052 0.019 DBMET03508 | DBMET03506 | |
| 0.048 | 0.062 | 0.274 | Selectin antagonist | 0.274 0.007 DBMET03509 | DBMET03509 | |
| 0.026 | 0.041 | 0.057 | 5-Alpha-reductase inhibitor | 0.057 0.016 DBMET03506 0.055 0.017 DBMET03507 | DBMET03506 | |
| 0.11 | 0.125 | 0.18 | Anticoagulant | 0.18 0.061 DBMET03506 0.143 0.087 DBMET03508 0.18 0.061 DBMET03509 | DBMET03509 | |
| 0.035 | 0.05 | 0.065 | GP IIb/IIIa receptor antagonist | 0.065 0.026 DBMET03506 0.044 0.037 DBMET03508 | DBMET03506 | |
| 0.047 | 0.062 | 0.063 | Neuraminidase inhibitor | 0.063 0.04 DBMET03509 | DBMET03509 | |
| 0.02 | 0.037 | 0.025 | Vanilloid 2 agonist | 0.025 0.018 DBMET03509 | DBMET03509 | |
| 0.026 | 0.045 | 0.069 | Farnesoid X receptor agonist | 0.069 0.007 DBMET03506 0.042 0.021 DBMET03508 | DBMET03506 | |
| 0.036 | 0.055 | 0.049 | Neuraminidase (Influenza A) inhibitor | 0.049 0.026 DBMET03509 | DBMET03509 | |
| 0.072 | 0.095 | 0.115 | Triose-phosphate isomerase inhibitor | 0.115 0.035 DBMET03506 0.091 0.058 DBMET03507 0.085 0.068 DBMET03508 | DBMET03506 | |
| 0.047 | 0.072 | 0.075 | Adenine nucleotide translocase inhibitor | 0.075 0.012 DBMET03509 | DBMET03509 | |
| 0.008 | 0.034 | 0.023 | Peroxisome proliferator-activated receptor alpha antagonist | 0.023 0.014 DBMET03506 | DBMET03506 | |
| 0.023 | 0.051 | 0.046 | G protein-coupled receptor agonist | 0.046 0.02 DBMET03506 | DBMET03506 | |
| 0.16 | 0.191 | 0.291 | Lipoxygenase inhibitor | 0.196 0.145 DBMET03506 0.174 0.171 DBMET03507 0.291 0.076 DBMET03508 | DBMET03508 | |
| 0.026 | 0.058 | 0.053 | Antibiotic Aminoglycoside-like | 0.053 0.012 DBMET03509 | DBMET03509 | |
| 0.043 | 0.078 | 0.057 | Protease activated receptor antagonist | 0.057 0.051 DBMET03506 | DBMET03506 | |
| 0.033 | 0.069 | 0.046 | Plasminogen activator inhibitor antagonist | 0.046 0.037 DBMET03506 | DBMET03506 | |
| 0.049 | 0.087 | 0.065 | Neuraminidase (influenza) inhibitor | 0.065 0.044 DBMET03509 | DBMET03509 | |
| 0.024 | 0.063 | 0.039 | Glutamate (mGluR3) agonist | 0.039 0.011 DBMET03506 0.037 0.013 DBMET03507 0.031 0.026 DBMET03508 | DBMET03506 | |
| 0.079 | 0.122 | 0.199 | Alkylator | 0.199 0.027 DBMET03509 | DBMET03509 | |
| 0.009 | 0.057 | 0.038 | Prostaglandin H2 antagonist | 0.029 0.014 DBMET03506 0.038 0.007 DBMET03508 | DBMET03508 | |
| 0.066 | 0.115 | 0.108 | Transcription factor NF kappa B stimulant | 0.083 0.063 DBMET03508 0.108 0.032 DBMET03509 | DBMET03509 | |
| 0.1 | 0.151 | 0.164 | Sigma receptor agonist | 0.164 0.076 DBMET03506 0.146 0.088 DBMET03508 | DBMET03506 | |
| 0.071 | 0.125 | 0.098 | Adenylate cyclase inhibitor | 0.098 0.086 DBMET03506 | DBMET03506 | |
| 0.049 | 0.103 | 0.07 | Glutamate (mGluR7) antagonist | 0.07 0.042 DBMET03506 | DBMET03506 | |
| 0.004 | 0.059 | 0.012 | Glutamate (mGluR6) agonist | 0.012 0.008 DBMET03506 | DBMET03506 | |
| 0.159 | 0.219 | 0.406 | Immunomodulator | 0.406 0.042 DBMET03509 | DBMET03509 | |
| 0.054 | 0.116 | 0.132 | NMDA receptor antagonist | 0.132 0.03 DBMET03506 | DBMET03506 | |
| 0.051 | 0.117 | 0.073 | Glycine receptor agonist | 0.073 0.049 DBMET03506 0.068 0.059 DBMET03507 | DBMET03506 | |
| 0.065 | 0.133 | 0.192 | Topoisomerase II inhibitor | 0.157 0.046 DBMET03507 0.192 0.035 DBMET03509 | DBMET03509 | |
| 0.062 | 0.132 | 0.092 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.092 0.063 DBMET03506 0.082 0.078 DBMET03507 | DBMET03506 | |
| 0.019 | 0.091 | 0.037 | Glutamate (mGluR group II) antagonist | 0.037 0.029 DBMET03506 | DBMET03506 | |
| 0.142 | 0.221 | 0.234 | DNA synthesis inhibitor | 0.191 0.137 DBMET03506 0.173 0.165 DBMET03508 0.234 0.079 DBMET03509 | DBMET03509 | |
| 0.069 | 0.16 | 0.091 | Phosphodiesterase 6D inhibitor | 0.091 0.073 DBMET03509 | DBMET03509 | |
| 0.063 | 0.156 | 0.081 | Estrogen-related receptor beta agonist | 0.081 0.065 DBMET03506 | DBMET03506 | |
| 0.065 | 0.162 | 0.081 | T cell inhibitor | 0.081 0.06 DBMET03506 | DBMET03506 | |
| 0.028 | 0.124 | 0.057 | Carbamoyl phosphate synthetase inhibitor | 0.057 0.046 DBMET03506 | DBMET03506 | |
| 0.137 | 0.235 | 0.19 | RNA-directed DNA polymerase inhibitor | 0.168 0.157 DBMET03506 0.19 0.115 DBMET03508 | DBMET03508 | |
| 0.012 | 0.118 | 0.026 | Thyroid hormone agonist | 0.026 0.018 DBMET03506 | DBMET03506 | |
| 0.073 | 0.181 | 0.134 | Cell adhesion inhibitor | 0.108 0.076 DBMET03506 0.11 0.074 DBMET03508 0.134 0.056 DBMET03509 | DBMET03509 | |
| 0.021 | 0.134 | 0.063 | Dopamine transporter inhibitor | 0.063 0.023 DBMET03507 | DBMET03507 | |
| 0.036 | 0.149 | 0.054 | Pregnane X receptor antagonist | 0.054 0.049 DBMET03506 | DBMET03506 | |
| 0.06 | 0.175 | 0.108 | AMP-activated protein kinase stimulant | 0.108 0.06 DBMET03509 | DBMET03509 | |
| 0.147 | 0.266 | 0.243 | Tyrosine 3 hydroxylase inhibitor | 0.235 0.084 DBMET03506 0.243 0.075 DBMET03507 0.209 0.121 DBMET03508 | DBMET03507 | |
| 0.06 | 0.18 | 0.106 | Cholinergic antagonist | 0.106 0.088 DBMET03506 | DBMET03506 | |
| 0.055 | 0.178 | 0.095 | Thioredoxin inhibitor | 0.095 0.054 DBMET03508 | DBMET03508 | |
| 0.058 | 0.185 | 0.102 | Acetylcholine antagonist | 0.102 0.09 DBMET03506 | DBMET03506 | |
| 0.026 | 0.157 | 0.056 | Androgen agonist | 0.056 0.047 DBMET03506 | DBMET03506 | |
| 0.012 | 0.144 | 0.045 | NMDA receptor subunit 3A antagonist | 0.045 0.022 DBMET03506 | DBMET03506 | |
| 0.156 | 0.292 | 0.251 | Calcium channel activator | 0.251 0.145 DBMET03506 0.226 0.177 DBMET03507 | DBMET03506 | |
| 0.151 | 0.289 | 0.199 | 5 Hydroxytryptamine uptake stimulant | 0.188 0.178 DBMET03506 0.199 0.153 DBMET03507 | DBMET03507 | |
| 0.049 | 0.19 | 0.114 | Cystathionine beta-synthase inhibitor | 0.108 0.069 DBMET03506 0.114 0.063 DBMET03507 0.113 0.064 DBMET03508 | DBMET03507 | |
| 0.032 | 0.178 | 0.068 | Topoisomerase II alpha inhibitor | 0.068 0.063 DBMET03509 | DBMET03509 | |
| 0.017 | 0.166 | 0.044 | NMDA receptor subunit 3B antagonist | 0.044 0.031 DBMET03506 | DBMET03506 | |
| 0.041 | 0.218 | 0.121 | HIV-1 integrase (Overall Integration) inhibitor | 0.104 0.051 DBMET03506 0.121 0.039 DBMET03507 0.082 0.075 DBMET03508 | DBMET03507 | |
| 0.042 | 0.225 | 0.092 | UDP-glucose 4-epimerase inhibitor | 0.092 0.071 DBMET03509 | DBMET03509 | |
| 0.098 | 0.284 | 0.208 | DNA damaging | 0.208 0.109 DBMET03509 | DBMET03509 | |
| 0.023 | 0.234 | 0.054 | Heparanase inhibitor | 0.054 0.035 DBMET03509 | DBMET03509 | |
| 0.063 | 0.319 | 0.195 | Antiamyloidogenic | 0.195 0.103 DBMET03509 | DBMET03509 | |
| 0.024 | 0.286 | 0.15 | Topoisomerase I inhibitor | 0.09 0.079 DBMET03507 0.15 0.041 DBMET03509 | DBMET03509 | |
| 0.028 | 0.344 | 0.098 | GABA C receptor agonist | 0.098 0.069 DBMET03506 | DBMET03506 | |
| 0.007 | 0.398 | 0.064 | Purinergic P2X3 antagonist | 0.064 0.007 DBMET03507 | DBMET03507 | |
| 0.019 | 0.419 | 0.107 | DNA intercalator | 0.107 0.067 DBMET03507 | DBMET03507 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |